Vicagrel

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527302

CAS#: 1314081-53-2

Description: Vicagrel, an acetate derivative of Clopidogrel, is a P2Y12 platelet inhibitor potentially for the treatment of thrombosis.


Price and Availability

Size
Price

Size
Price

Size
Price

Vicagrel is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 527302
Name: Vicagrel
CAS#: 1314081-53-2
Chemical Formula: C18H18ClNO4S
Exact Mass: 379.0645
Molecular Weight: 379.855
Elemental Analysis: C, 56.92; H, 4.78; Cl, 9.33; N, 3.69; O, 16.85; S, 8.44


Synonym: Vicagrel; Clopidogrel

IUPAC/Chemical Name: methyl 2-(2-acetoxy-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate

InChi Key: GNHHCBSBCDGWND-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H18ClNO4S/c1-11(21)24-16-9-12-10-20(8-7-15(12)25-16)17(18(22)23-2)13-5-3-4-6-14(13)19/h3-6,9,17H,7-8,10H2,1-2H3

SMILES Code: O=C(OC)C(C1=CC=CC=C1Cl)N2CCC3=C(C=C(OC(C)=O)S3)C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Qiu ZX, Gao WC, Dai Y, Zhou SF, Zhao J, Lu Y, Chen XJ, Li N. Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel. Front Pharmacol. 2016 Oct 7;7:366. PubMed PMID: 27774067; PubMed Central PMCID: PMC5054534.

2: Qiu Z, Li N, Song L, Lu Y, Jing J, Parekha HS, Gao W, Tian F, Wang X, Ren S, Chen X. Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel. Pharm Res. 2014 Jan;31(1):238-51. doi: 10.1007/s11095-013-1158-5. PubMed PMID: 24037619.

3: Qiu Z, Li N, Wang X, Tian F, Liu Q, Song L, Fan Z, Lu Y, Chen X. Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. J Pharm Sci. 2013 Feb;102(2):741-9. doi: 10.1002/jps.23394. PubMed PMID: 23192851.

4: Shan J, Zhang B, Zhu Y, Jiao B, Zheng W, Qi X, Gong Y, Yuan F, Lv F, Sun H. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J Med Chem. 2012 Apr 12;55(7):3342-52. doi: 10.1021/jm300038c. PubMed PMID: 22428882.

5: Xu X, Zhao X, Yang Z, Wang H, Meng X, Su C, Liu M, Fawcett JP, Yang Y, Gu J. Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration. Molecules. 2016 May 30;21(6). pii: E704. doi: 10.3390/molecules21060704. PubMed PMID: 27248988.